Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maziyar Kalani

Neurological Surgery Scottsdale, AZ Medical Doctor

NPI 1235363888 CMS profile 101864

13400 E Shea Blvd, Scottsdale, AZ 85259

Open in the dashboard

General payments

$334,060

542 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maziyar Kalani of Scottsdale, AZ is reported in the CMS Open Payments database as having received $334,060 across 542 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75,081 142
2024 General $70,787 114
2023 General $28,636 92
2022 General $39,085 102
2021 General $109,007 33
2020 General $10,212 38
2019 General $1,253 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maziyar Kalani
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Maziyar Kalani were reported at $75,081. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Maziyar Kalani Neurological Surgery median Middle half National median
2019 $1,253 $582 $138–$3,006 $163
2020 $10,212 $294 $76–$2,174 $114
2021 $109,007 $387 $105–$2,432 $132
2022 $39,085 $542 $139–$2,989 $149
2023 $28,636 $534 $145–$2,697 $160
2024 $70,787 $574 $155–$3,046 $164
2025 $75,081 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NuVasive, Inc. $168,074 164 payments
  2. Medtronic, Inc. $87,108 199 payments
  3. Globus Medical, Inc. $31,355 44 payments
  4. Evolution Spine, LLC $18,532 5 payments
  5. Carlsmed, Inc. $18,412 26 payments
  6. Stryker Corporation $3,272 43 payments
  7. Medtronic USA, Inc. $1,980 8 payments
  8. icotec Medical Inc. $1,835 15 payments
  9. Carbofix Spine Inc $1,155 13 payments
  10. Alphatec Spine, Inc $888 7 payments
  11. Other $1,449 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $117,522 4 payments
  2. Consulting Fee $111,219 59 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $48,950 9 payments
  4. Travel and Lodging $36,264 156 payments
  5. Food and Beverage $20,105 314 payments
Products named General payments · program years 2019–2025
  1. XLIF Spine/Spine Surgery $171,090 126 payments
  2. UNID_PASS $19,694 33 payments
  3. aprevo $18,171 24 payments
  4. Integrated ALIF System $17,522 3 payments
  5. KYPHON EXPRESS II KYPHOPAK TRAY $11,940 13 payments
  6. MAZOR X SYSTEM $10,061 28 payments
  7. ELSA $7,601 6 payments
  8. XLIF Spine/Spine Surgery $7,397 19 payments
  9. CD HORIZON SPINAL SYSTEM $5,518 6 payments
  10. EXCELSIUS GPS $4,667 5 payments
  11. Other $23,462 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Neurosurgery: 83

Drug cost

$85

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 12 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$346,602

Medicare's payments for the services billed

Medicare patients

359

Average age 73

Services billed

1,147

178 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 29%
Depression 29%
Chronic kidney disease 28%
Osteoporosis 26%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

542 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record